Applied Spectral Imaging

Carlsbad, CA. – April 16, 2015 – Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced today that it has received clearance from the South Korean Ministry of Food and Drug Safety (MFDS) for its GenASIs HiPath image capture and analysis...

FDA Clearance for GenASIs™ HiPath IHC Family for HER2, ER, PR and Ki67

A partnership making R2R workflow (“Reagent to Report”) a reality by combining Biocare’s automated IHC instrumentation and reagents with ASI’s computer-aided imaging and analysis

Enabling end-to-end, automated workflow for FISH and Karyotyping, from slide production to sample analysis and result reporting

Delivering a state-of-the-art integrated computerized analysis instrument and cell enrichment solution

World's First FDA Cleared ALK Automated Gene Scanner for Lung Cancer Therapy-Selection Available from ASI Targeting the Right Treatment for the Right Patient in ALK Therapy Selection for Non-Small-Cell Lung Cancer

GenASIs Go-Path – Industry’s Most Advanced Computer Aided Membrane and Nuclear Immunohistochemistry Imaging and Analysis Platform

GenASIs Version 7.2 introduces major enhancements to ASI’s offering of existing imaging applications and positions ASI as a leader in both cytogenetic and pathology imaging and analysis.

ASI’s GenASIs automated scanning and image analysis system for detection and quantifying chromosome 17 and the HER-2/neu gene has been cleared by the United States Food and Drug Administration (FDA) for marketing in the US

GenASIs Scan & Analysis cleared for FISH Detection and Analysis of chromosomal abnormalities in urine specimens